The FDA has issued a Complete Response Letter regarding the NDA for govorestat for the treatment of classic galactosemia.
Geriatric care for LGBTQ+ adults who live in rural communities requires cultural competence training and diverse health care teams.
About one-third of US adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...
Denifanstat treatment significantly improves liver disease activity among individuals with metabolic dysfunction-associated steatohepatitis.
For low-risk pregnancies, planned home births are as safe as planned birth center births, according to a study published.
Diabetic retinopathy screening with AI was associated with higher referral rates to optical coherence tomography but remains underutilized.
Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.
Current prenatal multivitamin and mineral (PMVM) labels are misleading and often exclude the presence of heavy metals.
Long-term sex hormone treatment in transgender individuals can lead to significant changes in body composition and risk factors for cardiovascular disease.
Vaccination of 27- to 45-year-olds ("mid-adults") against human papillomavirus (HPV) is less cost-effective than vaccination of younger persons (aged 9 to 26 years).
The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.
Risk for all-cause mortality and MACEs are affected by calcified and low-attenuation plaque burdens in patients with chronic kidney disease.